Status:
COMPLETED
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
Lead Sponsor:
AstraZeneca
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of AZD6912 administered subcutaneously (SC) in healthy participants.
Detailed Description
In this First-In-Human (FiH) study, eligible participants will be randomly assigned to 6 cohorts in a 3:1 ratio to receive either a single dose of AZD6912 SC or placebo. The first 2 participants in ea...
Eligibility Criteria
Inclusion
- Females must have a negative pregnancy test.
- Contraceptive use by males and females should be consistent with local regulations.
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
- For optional Japanese participants only:
- Participants must be of Japanese descent defined as: first generation (born to 2 Japanese parents and 4 Japanese grandparents).
- Born in Japan, and not have lived outside Japan for more than 5 years.
- Lifestyle, including diet, must not have significantly changed since leaving Japan.
Exclusion
- History of any clinically important disease or disorder.
- Current or recurrent disease of clinical significance that could affect clinical assessments or clinical laboratory evaluations.
- Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
- History of congenital or acquired immunodeficiency or complement deficiency or an underlying condition that predisposes to infection.
- History of any Neisseria infection, unexplained, recurrent infections, or infection requiring treatment with systemic antibiotics.
- Evidence of hepatitis B infection (positive for HBsAg or positive for anti-HBcAb) or hepatitis C viral infection (HCV Abs or hepatitis C RNA positive) or HIV infection (positive for HIV type 1 or type 2 Abs).
- Participants testing positive for COVID-19 prior to dosing.
- Any cardiac abnormalities.
- A CAP activity \< 60% at screening.
- Known or suspected history of drug abuse, history of alcohol abuse or smoking.
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 16 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06115967
Start Date
November 15 2023
End Date
October 16 2025
Last Update
December 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Montreal, Quebec, Canada, H3P 3P1
2
Research Site
Harrow, United Kingdom, HA1 3UJ